• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

Introduction to 6-Fluoro-2-hydrazinyl-1,3-benzothiazole (CAS No. 78364-55-3)

6-Fluoro-2-hydrazinyl-1,3-benzothiazole, identified by its Chemical Abstracts Service (CAS) number 78364-55-3, is a significant compound in the realm of pharmaceutical and medicinal chemistry. This heterocyclic organic molecule, featuring a benzothiazole core with a fluoro and hydrazinyl substituent, has garnered attention due to its versatile applications in drug discovery and development. The structural features of this compound contribute to its unique chemical properties, making it a valuable scaffold for designing novel therapeutic agents.

The benzothiazole moiety is a well-known pharmacophore in medicinal chemistry, frequently incorporated into molecules targeting various biological pathways. Its presence in 6-Fluoro-2-hydrazinyl-1,3-benzothiazole enhances the compound's potential as an intermediate in synthesizing bioactive molecules. The fluoro substituent, in particular, is known for its ability to modulate metabolic stability and binding affinity, which are critical factors in drug design. The hydrazinyl group adds another layer of reactivity, enabling further functionalization and diversification of the molecular structure.

Recent advancements in synthetic methodologies have improved the accessibility of 6-Fluoro-2-hydrazinyl-1,3-benzothiazole, facilitating its use in large-scale pharmaceutical research. Researchers have leveraged modern techniques such as transition-metal-catalyzed cross-coupling reactions and microwave-assisted synthesis to optimize the production process. These innovations have not only enhanced yield but also reduced the environmental impact of its synthesis, aligning with the growing emphasis on sustainable chemistry practices.

In the context of drug discovery, 6-Fluoro-2-hydrazinyl-1,3-benzothiazole has been explored as a precursor for compounds targeting neurological disorders. Studies have indicated its potential in modulating enzymes and receptors involved in conditions such as Alzheimer's disease and Parkinson's disease. The fluorine atom's electronic properties can fine-tune interactions with biological targets, potentially leading to more effective and selective therapeutic agents. Additionally, the hydrazinyl group provides a site for further derivatization, allowing chemists to tailor the molecule's pharmacokinetic profile.

The compound's utility extends beyond neurological applications. Emerging research suggests its relevance in oncology, where benzothiazole derivatives are being investigated for their anti-cancer properties. The structural motifs present in 6-Fluoro-2-hydrazinyl-1,3-benzothiazole can interact with key proteins and kinases involved in tumor growth and progression. Preclinical studies have demonstrated promising results in cell culture models, indicating that further exploration could yield novel chemotherapeutic agents.

The role of computational chemistry has also been instrumental in understanding the behavior of 6-Fluoro-2-hydrazinyl-1,3-benzothiazole. Molecular modeling techniques allow researchers to predict how this compound might interact with biological targets at the atomic level. This approach has accelerated the drug discovery process by enabling virtual screening of potential candidates before experimental validation. Such integrative strategies highlight the synergy between experimental chemistry and computational science in developing next-generation pharmaceuticals.

Safety considerations are paramount when handling 6-Fluoro-2-hydrazinyl-1,3-benzothiazole. While it is not classified as a hazardous material under standard regulatory frameworks, proper handling protocols must be followed to ensure worker safety and environmental protection. Storage conditions should be controlled to prevent degradation or unwanted reactions. Furthermore, researchers must adhere to ethical guidelines when conducting experiments involving this compound.

The future prospects of 6-Fluoro-2-hydrazinyl-1,3-benzothiazole are promising, with ongoing research aimed at expanding its applications across multiple therapeutic areas. Collaborative efforts between academia and industry are essential to translate laboratory findings into clinical reality. As our understanding of molecular interactions continues to evolve, compounds like this will play an increasingly vital role in addressing complex diseases.

• 615-21-4(1,3-benzothiazol-2-ylhydrazine)
• 119256-40-5(4,6-difluoro-1,3-benzothiazol-2-amine)
• 14889-08-8(Naphtho[2,1-d]thiazole,2-hydrazinyl-)
• 121343-91-7(Benzothiazole,2-(2,2-dimethylhydrazinyl)-)
• 20358-07-0(2-Amino-5-fluorobenzothiazole)
• 16942-72-6(Naphtho[1,2-d]thiazole,2-hydrazinyl-)
• 20358-06-9(4-Fluorobenzo[d]thiazol-2-amine)
• 348-40-3(6-fluorobenzo[d]thiazol-2-amine)
• 186457-64-7(Formaldehyde,2-(2-benzothiazolyl)hydrazone)
• 193828-79-4(Benzothiazole,5-fluoro-2-hydrazinyl-)